Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $79,682.52 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 1,453 shares of the stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $54.84, for a total value of $79,682.52. Following the sale, the chief operating officer now directly owns 196,594 shares in the company, valued at $10,781,214.96. This trade represents a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jonathan Young also recently made the following trade(s):

• On Tuesday, June 10th, Jonathan Young sold 2,493 shares of Akero Therapeutics stock. The stock was sold at an average price of $53.99, for a total transaction of $134,597.07.

Akero Therapeutics Stock Performance

Shares of AKRO stock traded down $0.17 during mid-day trading on Monday, reaching $54.03. The stock had a trading volume of 1,271,985 shares, compared to its average volume of 1,014,119. Akero Therapeutics, Inc. has a 1-year low of $21.02 and a 1-year high of $58.40. The firm has a market cap of $4.31 billion, a price-to-earnings ratio of -27.71 and a beta of -0.16. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. The business's fifty day moving average is $45.88 and its 200-day moving average is $41.25.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of ($1.01) by $1.91. On average, research analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on AKRO. Bank of America raised their price objective on Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research note on Tuesday, May 27th. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Citigroup lowered their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Finally, HC Wainwright increased their price target on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $82.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Tema Etfs LLC purchased a new position in shares of Akero Therapeutics in the fourth quarter worth about $894,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Akero Therapeutics in the fourth quarter valued at approximately $840,000. RTW Investments LP increased its holdings in shares of Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock valued at $190,840,000 after purchasing an additional 940,388 shares during the last quarter. Ameriprise Financial Inc. purchased a new position in Akero Therapeutics during the fourth quarter worth approximately $422,000. Finally, Two Sigma Advisers LP boosted its stake in Akero Therapeutics by 195.7% during the fourth quarter. Two Sigma Advisers LP now owns 41,100 shares of the company's stock worth $1,143,000 after buying an additional 27,200 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.